DNA Genotek’s Sample Collection Kit Selected by Genomind for Personalized Medicine Test
Genecept MoodÃ¢“¢ Assay Combines DNA Collection with a Panel of Genetic Tests and Report for Physicians
Ottawa, ON (Vocus/PRWEB) April 18, 2011
DNA Genotek Inc. a leading provider of products for biological sample collection, stabilization and preparation, announced today that its Oragene®”¢DNA product has been selected by Genomind, LLC as the sample collection kit for the Genecept MoodÃ¢“¢ Assay, a saliva-based psychiatric genetic test.
The Genecept MoodÃ¢“¢ Assay is a highly specialized personalized medicine genetic test that is designed to assist clinicians in determining if a patient has a specific genetic polymorphism that may be associated with a psychiatric condition. The test provides the clinician with information on specific patient genotypes. Such information may enable the physician to be more selective regarding medication choice and lessen the experimentation and guesswork often associated with determining appropriate medication.
Less evidence exists to guide treatment decisions in psychiatry than almost any other area of medicine. Because there are no current clinical biomarker tools to guide treatment, a trial and error approach is prevalent. The Genecept MoodÃ¢“¢ Assay is prescribed by physicians and available online at http://www.genomind.com. In order to complete the test, the patient provides a small saliva sample using the Oragene”¢DNA sample collection device, which is then mailed to Genomind’s lab for genetic analysis. Within 3-5 business days, a report is provided to the physician through a secure website portal. The report contains easy to understand test results and corresponding interpretation.
Oragene”¢DNA is ideal for this type of genetic testing as it addresses sample collection challenges inherent with traditional collection methods such as blood draws or buccal swabs. Traditional methods are often too costly and invasive, or may not reliably provide enough high-quality DNA to enable the determination of a tailored approach to treatment of disease.
“Genomind was formed to facilitate the adoption of personalized medicine into psychiatry. One of the challenges for us was to make a test for behavioral health that is non-invasive and easily accessible to clinicians, patients and our lab”, said Ronald I. Dozoretz, MD, Founder, Chairman and CEO, Genomind. “The ease-of-use and high yield results of Oragene”¢DNA, combined with its outstanding reputation for quality made it the natural choice for the Genecept MoodÃ¢“¢ Assay test.”
“Genomind’s selection of the Oragene”¢DNA product is another exciting validation of our work to deliver high-quality, non-invasive sample collection devices for personalized medicine applications such as behavioral health”, said Ian Curry, president and CEO, DNA Genotek Inc. “
About Genomind, LLC:
Genomind, LLC is a company specializing in neuropsychiatric personalized medicine and was formed to facilitate the adoption of Personalized Medicine into psychiatry by providing genetic information to better understand the patient. Genomind was founded by Ronald I. Dozoretz, MD, in 2009, and the company is advised by a group of renowned experts in the fields of human genetics and neuropsychiatric medicine. More information is available at: http://www.genomind.com.
About DNA Genotek:
DNA Genotek focuses on providing high-quality biological sample collection products. The company’s Oragene family of products provides a non-invasive way to collect and preserve large amounts of DNA or RNA from saliva. The company also offers a family of products for collecting DNA from animals and livestock. The reliability and ease-of-use of the company’s products have resulted in rapid adoption at top-tier health research institutions globally, including Harvard, Stanford, Cambridge, and Johns Hopkins. DNA Genotek markets its products worldwide and has established a global customer base in over 100 countries. For more information about DNA Genotek, visit http://www.dnagenotek.com.
# # #
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2011/4/prweb8307143.htm